Home4547 • TYO
add
Kissei Pharmaceutical Co Ltd
Nakaraang pagsara
¥4,095.00
Sakop ng araw
¥3,890.00 - ¥4,075.00
Sakop ng taon
¥3,000.00 - ¥4,270.00
Market cap
187.09B JPY
Average na Volume
101.60K
P/E ratio
16.16
Dividend yield
2.20%
Primary exchange
TYO
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (JPY) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 21.30B | 20.59% |
Gastos sa pagpapatakbo | 10.89B | 30.69% |
Net na kita | 1.14B | -52.63% |
Net profit margin | 5.37 | -60.69% |
Kita sa bawat share | — | — |
EBITDA | 765.00M | -45.65% |
Aktuwal na % ng binabayarang buwis | 29.99% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (JPY) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 49.96B | 5.10% |
Kabuuang asset | 260.34B | 12.27% |
Kabuuang sagutin | 39.57B | 30.80% |
Kabuuang equity | 220.77B | — |
Natitirang share | 44.21M | — |
Presyo para makapag-book | 0.82 | — |
Return on assets | -0.36% | — |
Return on capital | -0.42% | — |
Cash Flow
Net change in cash
| (JPY) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 1.14B | -52.63% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Itinatag
Ago 9, 1946
Headquarters
Website
Mga Empleyado
1,779
